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Forever Young*Pasquale Santangeli, MD, Francis E. Marchlinski, MDSEE PAGE 2455T he efﬁcacy of pulmonary vein isolation (PVI)as a treatment for drug-refractory atrialﬁbrillation (AF) has been established through
more than 15 years of clinical studies, which have
shown consistent, reproducible results worldwide.
The PVI technique has evolved to include antral isola-
tion to enhance safety and efﬁcacy. However, the suc-
cess rate with current PVI techniques remains
suboptimal, with single-procedure efﬁcacy ranging
between 50% and 75% (1).
Patients with persistent AF experience the worst
outcomes, leading to the hypothesis that additional
ablation beyond the pulmonary veins (PVs) may be
required to improve success in these patients. Addi-
tional targets have focused on putative mechanisms
responsible for AF maintenance, such as empirical
linear ablation (1) or ablation of AF focal sources
or rotors identiﬁed using various computational
mapping techniques (2,3). This hypothesis, although
sound from a mechanistic perspective related to AF
maintenance, is ﬂawed by the fact that none of the
studies comparing PVI alone with other non-PV
ablation strategies (with or without PVI) ever
achieved the desired goal of durable PVI: PV recon-
nection rules in patients experiencing post-ablation
arrhythmia recurrence (4). In the presence of PV
reconnection, AF recurrences should neither be used
to claim ineffectiveness of PVI nor used to support
the necessity of additional extra-PV ablation,*Editorials published in the Journal of the American College of Cardiology
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contents of this paper to disclose.although confusion in this sense may easily arise
when facing data from published studies (Figure 1).
The results of the randomized RADAR-AF (Radio-
frequency Ablation of Drivers of Atrial Fibrillation)
trial published in this issue of the Journal should be
viewed in this context (3). The RADAR-AF trial tested
the hypothesis that localized high-frequency source
ablation (HFSA) is noninferior to conventional antral
PVI in patients with paroxysmal AF and that a hybrid
strategy of PVI plus HFSA is superior to PVI alone in
patients with persistent AF. High-frequency sources
(HFS) have been implicated in the maintenance of
human AF, and HFSA has achieved arrhythmia con-
trol in patients with drug-refractory AF in uncon-
trolled case series (5). However, no prior clinical
study compared HFSA with conventional PVI as a
treatment strategy for drug-refractory AF.The primary endpoint of the RADAR-AF trial was
freedom from AF off of antiarrhythmic drugs at
6 months. Secondary endpoints included freedom
from AF at 1 year and procedural safety outcomes. In
brief, the study failed to meet the primary endpoint;
indeed, PVI only was superior to HFSA only at
6-month follow-up in patients with paroxysmal AF
and was equivalent to PVI plus HFSA in patients with
persistent AF. The study, however, did show that
HFSA-only ablation reached the secondary endpoint
of noninferiority at 1 year compared with PVI alone in
patients with paroxysmal AF (79% vs. 81%) and
trended toward higher procedure-related complica-
tions with PVI (14% vs. 5%).
To what extent can the ﬁndings of RADAR-AF be
generalized to the reader’s patients? The main re-
sults appear valid; the trial was well conducted and
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In this “hypothetical” trial of 200 patients (pts) undergoing pulmonary vein isolation (PVI),
70% reported survival free from recurrent atrial ﬁbrillation (AF) at 1 year. AF recurrences
over follow-up were largely driven by patients with pulmonary vein (PV) reconnection.
This does not imply that PVI per se is not effective as a treatment strategy for AF or that
additional non-PV ablation is necessary, because the success rate in the subgroup with
permanent PVI is nearly perfect (98%).
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However, caution is necessary when interpreting the
secondary endpoints, for which the study was not
speciﬁcally designed and likely not powered. For
instance, the higher rate of complications occurring
in the PVI arm of the paroxysmal AF group (14%),
which was driven by 4 pericardial effusions,
appeared substantially higher than that occurring
with the same procedure in patients with persistent
AF (3%). Without sufﬁcient power, it is hard to
evaluate the effect of chance in the reported
complications.
Overall, the main ﬁndings of the RADAR-AF trial
provide additional evidence supporting the current
recommendations for using PVI across the spectrum
of patients with AF (1). Importantly, PV reconnection
was conﬁrmed as the leading mechanism of AF
recurrence in both study groups. Even in patients
who underwent HFSA only, PV isolation was used to
eliminate HFS at most index procedures and, in those
with AF recurrences, all of the PVs harboring AF-
triggering HFS at repeat procedures had been iso-
lated at the index procedure. These ﬁndings further
support the notion that achieving permanent PVI
should be the main goal of catheter-based approaches
to treat AF, but it remains a big challenge. In this
regard, generalization of the RADAR-AF results is
still questionable, due to the variability in ablation
techniques and approaches, which can affect PVI
durability and, therefore, procedure efﬁcacy. For
example, for several years we have been implement-
ing strategies to enhance catheter stability to increase
the effectiveness of ablation lesions, decrease the
chance of chronic PV reconnection, and ultimately
improve the success rate (6). These strategies include
general anesthesia with jet ventilation to minimize
respiratory movement, steerable sheaths, periproce-
dural monitoring of tissue-catheter contact and lesion
formation with intracardiac echocardiography, and
the use of adenosine to conﬁrm early persistence of
PVI. None of these tools was used in the RADAR-AF
trial, and their absence might have undervalued
an even greater beneﬁt of PVI when analyzing
arrhythmia-free survival at longer follow-up (1 year).
There are a few other considerations regarding the
protocol of this important study worth highlighting.
The procedural endpoint adopted for PVI in the
RADAR-AF study was entry block, and additional roof
linear ablation (without mandatory achievement of
conduction block) was performed but at the discre-
tion of the operator. In our experience, demonstra-
tion of exit block in addition to entry block is
clinically relevant, as unidirectional entry block (with
exit conduction) can be observed in up to 20% ofPVs (7). Also, no information was provided on
whether any effort was made to elicit acute PV
reconnection at the time of the index procedure with
intravenous adenosine or high-dose isoproterenol.
The latter could have increased the chance to elicit
and appropriately target latent non-PV triggers for AF
that seem clinically relevant in an important sub-
group of patients. Previous studies suggest that non-
PV locations with HFS are consistent with common
AF trigger sites, and empirical ablation of such sites
may have explained some of the beneﬁt of HFSA.
Finally, the discretionary use of linear roof abla-
tion might have diluted PVI effectiveness, as no
conclusive data support the beneﬁt of any left atrial
linear ablation (especially in paroxysmal AF); in
fact, evidence suggests that linear ablation may
be proarrhythmic, particularly if performed without
conﬁrming block. Given the good outcome with PVI
in both paroxysmal and persistent AF patients in
the RADAR-AF trial, these additional technical
modiﬁcations would only further support the pri-
macy and outcome of antral PVI and non-PV trigger
ablation.
In conclusion, the results of the RADAR-AF trial
should be considered as more evidence favoring
antral PVI in patients with either paroxysmal or
persistent AF. Future research efforts should be
directed toward the attainment and noninvasive
conﬁrmation of durable PVI. By achieving this goal,
we can unequivocally identify the smaller group of
patients who truly do not respond to effective PVI
only and may require different ablation approaches
and/or targets, including HFSA.
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2470In 1974, after 8 years away from the stage, during
which time he had become a father, Bob Dylan
released his 14th studio album, Planet Waves. The
album featured 2 versions of a song dedicated to his
son, where he wished him to stay “Forever Young”
(8). More than 15 years after its introduction, PVI
has stood the test of time and, in the words of
Bob Dylan, will likely stay “forever young” andconsistently important when performing AF ablation
procedures.
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